Abstract 1575P
Background
Exposure to secondhand smoke (SHS) can elevate the overall cancer risk for individuals who have never smoked. Smoke-free policies aim to protect non-smokers from the harmful effects of SHS and align with the guidelines set forth by the World Health Organization (WHO) Framework Convention on Tobacco Control. However, restrictions on smoking in outdoor public places are limited.
Methods
Between 2021 and 2024, the Spanish Association Against Cancer (SAAC) launched a program to enhance smoking prohibitions in outdoor areas. To do so, we first identified public places highly visited by smokers and vulnerable populations. Collaboration agreements were established with city halls, public organizations, and institutions interested in the project. These agreements involved advertising prohibiting smoking and vaping, smoke-free events, and training programs for the personnel responsible for enforcing these recommendations.
Results
Since the program's implementation, 358 collaboration agreements have been signed with 235 city halls through the 52 provinces of Spain. Most agreements (n=129, 36%) were launched to free urban and rural parks and green places from SHS. Other included outdoor sports centers and sports grounds (n=78,22%), universities (n=40,11%), and beaches (n=10, 3%). As a result of the good population and city halls' response to the initiative, the SAAC enforced the inclusion and regulation of outdoor smoke-free places in the new national comprehensive plan for the prevention of smoking.
Conclusions
Population-level initiatives to enforce smoke-free policies in outdoor places can result in new national legislation.
Clinical trial identification
Editorial acknowledgement
Legal entity responsible for the study
Spanish Association Against Cancer.
Funding
Has not received any funding.
Disclosure
All authors have declared no conflicts of interest.
Resources from the same session
1553P - Access to EMA approved drugs in Europe, disparities across a border
Presenter: Orla Fitzpatrick
Session: Poster session 10
1554P - Co payments in cancer patients: Analysis and estimating OOP
Presenter: Krishnamani Kalpathi
Session: Poster session 10
1555P - Estimating the social value of immuno-oncology (IO) therapies in Japan
Presenter: Tomoya Ohno
Session: Poster session 10
1556P - Current landscape of drug approvals for genitourinary (GU) cancers in North America and Europe
Presenter: Jose Tapia
Session: Poster session 10
1557P - The use of patient experience in UK NICE decision making in oncology
Presenter: Noemi Muszbek
Session: Poster session 10
1558P - Independent validation of the Breast Cancer Risk Assessment Tool (Gail model) for predicting breast cancer risk in Egyptian population
Presenter: Elaria Yacoub
Session: Poster session 10
1559P - Equity of access and clinical impact of genomic testing in patients with cancer in a UK early phase clinical trials unit
Presenter: Jonathan Poon
Session: Poster session 10
1560P - Optimal age versus real age in breast and gynaecological risk reducing surgery in BRCA1/2 carriers
Presenter: Alberta Ferrari
Session: Poster session 10
1561P - Targeted screening methodologies to select high risk individuals: LungFlag performance in Estonia Lung Cancer Screening Pilot
Presenter: Tanel Laisaar
Session: Poster session 10
1562P - The feasibility of polygenic risk score-based population screening for breast cancer: The experience from the BRIGHT study in Estonia
Presenter: Anni Lepland
Session: Poster session 10